Journal Article

DZNE-2025-00028

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Psychiatric Diagnoses and Their Treatment in Women With Breast Cancer: A Latent Class Analysis of 1062 Inpatients.

Schulze, J. B. ; Dörner, M.DZNE* ; Huber, M. ; Jordan, K.-D. ; Känel, R. v. ; Euler, S.

2025
Cancer Information Group Dallas, Tex.

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.clbc.2024.06.011

Abstract: Psycho-oncological support (POS) and psychopharmacological interventions are effective in treating psychiatric symptoms in patients with breast cancer. However, despite high prevalences of psychiatric disorders in patients with breast cancer, a significant proportion remains untreated.Data from 1062 breast cancer patients who had been diagnosed and treated at a Comprehensive Cancer Center between 2012 and 2019 were analyzed retrospectively. We descriptively evaluated the number of patients with a psychiatric diagnosis, POS and psychiatric medication. Latent class analysis was used to examine the relationship between ICD-10 coded psychiatric diagnoses, POS, psychiatric medication, and, as important prognostic factors, tumor stage and somatic comorbidity.31.5% of all patients had a psychiatric diagnosis, 20% received POS and up to 60% received psychiatric medication. Latent class analysis revealed three subgroups: 1) patients with a low cancer stage, low somatic comorbidity, no psychiatric diagnosis, no POS and no psychiatric medication; 2) patients with a low cancer stage, low somatic comorbidity, a psychiatric diagnosis, and a higher probability of POS and psychiatric medication than class 1 and class 3; 3) patients with advanced cancer stage, high somatic comorbidity, a higher probability of a psychiatric diagnosis and POS than class 1, and no psychiatric medication.This study indicated a high prevalence of psychiatric disorders among patients with breast cancer and a discrepancy between the number of patients having a psychiatric disorder and those receiving psychiatric medication. The identification of subgroups might contribute to better tailored treatment for those patients whose needs are insufficiently met.

Keyword(s): Humans (MeSH) ; Female (MeSH) ; Breast Neoplasms: psychology (MeSH) ; Breast Neoplasms: therapy (MeSH) ; Breast Neoplasms: pathology (MeSH) ; Mental Disorders: epidemiology (MeSH) ; Middle Aged (MeSH) ; Retrospective Studies (MeSH) ; Adult (MeSH) ; Latent Class Analysis (MeSH) ; Aged (MeSH) ; Comorbidity (MeSH) ; Prevalence (MeSH) ; Inpatients: psychology (MeSH) ; Inpatients: statistics & numerical data (MeSH) ; Prognosis (MeSH) ; Psychotropic Drugs: therapeutic use (MeSH) ; Breast cancer ; Psychiatric comorbidity ; Psychiatric medication ; Psychiatric treatment ; Psycho-oncology ; Psychotropic Drugs

---

Contributing Institute(s):

1. Mixed Cerebral Pathologies and Cognitive Aging (AG Schreiber)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---